Close
Open Enrollment ends on Dec. 7! Download the free guide to help weigh coverage options. 

Prescription Drugs

The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.

Part B Medicare Prescription Drug Inflation Rebate Program

The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part B drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.

Read More »

Improving the Effectiveness of Extra Help for Prescription Drugs

Medicare’s Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline, helping low- and moderate-income beneficiaries pay for coverage they would not otherwise be able to afford. But aspects of the program are woefully outdated, making it difficult for low- and moderate-income beneficiaries to access the help they need.

Read More »

Improving Access to Extra Help for Prescription Drugs

Current Medicare policies expose low- and moderate-income beneficiaries to excessive out-of-pocket costs. For those who qualify, the Low-Income Subsidy(LIS) program (also called “Extra Help”) can be a lifeline, helping them pay for Medicare coverage they would not otherwise be able to afford. But accessing this program presents challenges of its own. The application process is complex and fragmented, and the eligibility requirements are woefully outdated. As a result, many who need this assistance aren’t able to get it.

Read More »

Part B Medicare Prescription Drug Inflation Rebate Program

The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part B drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.

Improving the Effectiveness of Extra Help for Prescription Drugs

Medicare’s Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline, helping low- and moderate-income beneficiaries pay for coverage they would not otherwise be able to afford. But aspects of the program are woefully outdated, making it difficult for low- and moderate-income beneficiaries to access the help they need.

Improving Access to Extra Help for Prescription Drugs

Current Medicare policies expose low- and moderate-income beneficiaries to excessive out-of-pocket costs. For those who qualify, the Low-Income Subsidy(LIS) program (also called “Extra Help”) can be a lifeline, helping them pay for Medicare coverage they would not otherwise be able to afford. But accessing this program presents challenges of its own. The application process is complex and fragmented, and the eligibility requirements are woefully outdated. As a result, many who need this assistance aren’t able to get it.